WESTMINSTER, CA / ACCESS Newswire / May 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and health challenges, today announced that its subsidiary Clyra Medical Technologies, Inc. ("Clyra") has entered into a series of agreements to advance the sales and distribution of its medical products in the U.S. and abroad. Although none of the agreements require minimum product purchases, each agreement has the potential to generate material revenue for Clyra.
Dennis P. Calvert, CEO at BioLargo commented, "These agreements reflect the significant time, energy and resources Clyra has invested to meet client specifications and bring products to market. While no prediction can be made as to when the agreements will result in product sales, or the volume of sales, we believe each could be important as Clyra grows. We look forward to announcing more developments as the products go to market."
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. BioLargo is the majority owner of Clyra Medical Technologies, Inc. (www.ClyraMedical.com), a company focused on commercializing medical products based on BioLargo and Clyra's proprietary technologies.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/chemicals/biolargo-subsidiary-clyra-medical-advances-product-distribution-through-a-series-of-agree-1026956
